Vas­cepa sparkle set to light up Amar­in's fourth quar­ter rev­enue

Bask­ing in the glow of its keen­ly an­tic­i­pat­ed FDA ap­proval for its fish oil pill in the block­buster in­di­ca­tion of re­duc­ing car­dio­vas­cu­lar risk in pa­tients al­ready on statins, Amarin on Tues­day un­veiled its pre­lim­i­nary fourth-quar­ter rev­enue that beat Wall Street es­ti­mates.

Amarin ex­pects its to­tal 2019 rev­enue to come in at, or slight­ly ex­ceed, the up­per end of its pre­vi­ous­ly de­clared guid­ance of $410 mil­lion to $425 mil­lion, dri­ven by the sales of its flag­ship drug, Vas­cepa. That works out to rough­ly $140 mil­lion for the fourth quar­ter, north of the con­sen­sus pro­jec­tion of $131 mil­lion and Jef­feries’ es­ti­mate of $135 mil­lion, Jef­feries an­a­lysts wrote in a note.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.